Completion of US-FDA Inspection at the Company''s flagship facility in Bangalore

Business Updates View source PDF Explain this filing

STAR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.6%Reaction day

₹1145.00

prior close

₹1160.30

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+1.1%+0.5% vs market

Pharmaceuticals peers, median of 160sector+0.1%+1.5% vs sector

On the reaction day the stock moved 0.5 pts more than Nifty Microcap 250 and 1.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.7

10m

-1.0

15m

-1.5

30m

-0.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.6+1.1+0.5+0.1+1.5

Next day

-0.1+1.2-1.3+0.2-0.3

+3.5+2.8+0.7+1.4+2.1

+1.7+3.5-1.8+1.3+0.4

+1.2+3.5-2.3+1.6-0.4

-1.3+2.8-4.2+1.0-2.3

-5.9+2.8-8.7+0.4-6.3

15d

-7.4+4.2-11.6+0.7-8.2

-2.6+10.1-12.7+3.1-5.7

-8.3+10.0-18.3+7.2-15.5

-14.1+14.6-28.6+8.2-22.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 160Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

USFDA conducted a routine current Good Manufacturing Practices (cGMP) inspection at Strides Pharma's flagship Bangalore facility from May 12-20, 2026. The inspection concluded with the issuance of a Form 483 containing five observations, which are areas where the regulator has identified potential deviations from GMP standards. The company has stated it will respond to these observations within the prescribed timeframe and will update exchanges on any further developments.

Likely market impact

Form 483 observations indicate potential compliance concerns that could affect the company's ability to supply products to the US market if not adequately addressed. While this is a routine inspection finding rather than an outright rejection, it introduces regulatory risk for shareholders and may require close monitoring of the company's response and FDA's acceptance of corrective actions.